XML 50 R52.htm IDEA: XBRL DOCUMENT v2.4.0.6
Share-Based Payments (Tables)
 12 Months Ended
Dec. 31, 2012
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Share-based compensation expense included in consolidated statements of income
 
For the Years Ended December 31,
(In millions)
2012
 
2011
 
2010
Research and development
$
74.7

 
$
62.0

 
$
62.7

Selling, general and administrative
109.6

 
88.7

 
123.6

Restructuring charges
—

 
(0.6
)
 
6.8

Subtotal
184.3

 
150.1

 
193.1

Capitalized share-based compensation costs
(5.4
)
 
(4.5
)
 
(3.5
)
Share-based compensation expense included in total cost and expenses
178.9

 
145.6

 
189.6

Income tax effect
(53.4
)
 
(44.6
)
 
(60.3
)
Share-based compensation expense included in net income attributable to Biogen Idec Inc.
$
125.5

 
$
101.0

 
$
129.3
Summary of share-based compensation expense associated with each of our share-based compensating programs
 
For the Years Ended December 31,
(In millions)
2012
 
2011
 
2010
Stock options
$
2.3

 
$
5.9

 
$
26.1

Market stock units
23.3

 
14.6

 
10.0

Time-vested restricted stock units
93.0

 
89.6

 
129.4

Performance-vested restricted stock units settled in shares
0.1

 
1.0

 
5.3

Cash settled performance shares
60.4

 
32.7

 
15.0

Employee stock purchase plan
5.2

 
6.3

 
7.3

Subtotal
184.3

 
150.1

 
193.1

Capitalized share-based compensation costs
(5.4
)
 
(4.5
)
 
(3.5
)
Share-based compensation expense included in total cost and expenses
$
178.9

 
$
145.6

 
$
189.6
Weighted average assumptions to estimate fair value of stock option grants awarded
 
For the Years Ended December 31,
 
2012
 
2011
 
2010
Expected option life (in years)
**
 
**
 
4.5

Expected stock price volatility
**
 
**
 
30.8
%
Risk-free interest rate
**
 
**
 
2.0
%
Expected dividend yield
**
 
**
 
—
%
Per share grant-date fair value
**
 
**
 
$
16.52

**    There were no grants of stock options made in 2012 and 2011.
Stock option activity
 
Shares
 
Weighted
Average
Exercise
Price
Outstanding at December 31, 2011
1,691,000

 
$
52.75

Granted
—

 
$
—

Exercised
(765,000
)
 
$
50.72

Cancelled
(19,000
)
 
$
51.99

Outstanding at December 31, 2012
907,000

 
$
54.48
Tax benefit and cash received from stock option
 
For the Years Ended December 31,
(In millions)
2012
 
2011
 
2010
Tax benefit realized for stock options
$
20.9

 
$
47.5

 
$
16.0

Cash received from the exercise of stock options
$
38.8

 
$
291.9

 
$
160.0
Market stock units activity
 
Shares
 
Weighted
Average
Grant Date
Fair Value
Unvested at December 31, 2011
581,000

 
$
69.49

Granted (a)
319,000

 
$
134.95

Vested
(244,000
)
 
$
121.40

Forfeited
(50,000
)
 
$
75.94

Unvested at December 31, 2012
606,000

 
$
94.73
Assumptions used in valuation of market based stock units
 
For the Years Ended December 31,
 
2012
 
2011
Expected dividend yield
—%
 
—%
Range of expected stock price volatility
29.6% - 34.0%
 
25.7% - 33.4%
Range of risk-free interest rates
0.2% - 0.6%
 
0.3% - 1.9%
60 calendar day average stock price on grant date
$113.83 - $149.79
 
$66.78 - $101.16
Weighted-average per share grant date fair value
$134.95
 
$74.19
Cash settled performance shares
 
Shares
Unvested at December 31, 2011
562,000

Granted (a)
327,000

Vested
(280,000
)
Forfeited
(17,000
)
Unvested at December 31, 2012
592,000
Time-vested restricted stock units activity
 
Shares
 
Weighted
Average
Grant Date
Fair Value
Unvested at December 31, 2011
2,924,000

 
$
60.72

Granted (a)
1,013,000

 
$
124.54

Vested
(1,540,000
)
 
$
121.06

Forfeited
(210,000
)
 
$
79.55

Unvested at December 31, 2012
2,187,000

 
$
90.37
Performance-vested restricted stock units (PVRSUs) Activity
 
Shares
 
Weighted
Average
Grant Date
Fair Value
Unvested at December 31, 2011
47,000

 
$
49.34

Granted
—

 
$
—

Vested
(46,000
)
 
$
119.03

Forfeited
(70
)
 
$
49.65

Unvested at December 31, 2012
930

 
$
53.64
Shares issued under employee stock purchase plan
 
For the Years Ended December 31,
(In millions)
2012
 
2011
 
2010
Shares issued under ESPP
0.3

 
0.4

 
0.6

Cash received under ESPP
$
28.7

 
$
22.8

 
$
23.5